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Background: Clinical trials are essential for advancing cancer treatment. Yet, there is
limited data on their distribution and access in Europe. To ascertain the extent of
potential inequalities in access to clinical trials in Europe, we compared their distri-
bution among European countries.
Methods: The Clinicaltrials.gov database was searched for interventional clinical trials
in adults with neoplasms. Available data from phase I-III trials between 06/2009 to
06/2019 in Europe were retrieved. We considered the number of clinical trials
registered in each country and one “trial-entry” was defined as one trial/country.
Results: In total, 18454 trial-entries were identified, of which 12% were phase I, 10%
phase I/II, 32% phase II, 2% phase II/III and 44% phase III; 74% were industry-spon-
sored, 15% were academic and 11% were an academic/industry partnership. The
number of trials per country varied from 2.48 in Central/Eastern Europe to 5.33/100
000 inhabitants in Northern Europe. The proportion of phase I-II trials was higher in
the Southern and Western regions (13-15%) compared to Central/Eastern and
Northern regions (4-9%). The number of trial-entries/100 000 inhabitants/country
ranged from 0.14 (Albania) to 10.7 (Belgium). Between 2010 and 2018, the total
number of trials per country in Europe increased by 33%. The increase in early-phase
trials was larger (phase I-II, 61%) than in late-phase trials (phase II-III, 7%). Portugal,
Ireland, Finland, Greece and Norway registered the largest percentage increase in
early-phase trials, while Ireland, Spain, Norway, Italy and Belgium led the largest
percentage increase in late-phase trials. Five countries dominated in terms of an
increase in the absolute number of total trial-entries in both early- and late-phase
trials: Spain (90/40), France (45/16), UK (45/13), Italy (38/19) and Belgium (35/12).
During this period there was no significant variation in the distribution of industry and
academic sponsored trials but an increase in industry/academic partnerships was
observed (z 8%).
Conclusions: The number of clinical trials varies greatly among European regions
resulting in potential asymmetries in patients’ access to clinical trials. The disparities
in access to oncology trials need to be addressed by all the stakeholders.
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Background: Up-to-date cancer burden indicators provide an important source of
information for supporting political decision making, as well as for epidemiological
research and the general public. Nevertheless, observed cancer incidence and mor-
tality suffer from an inherent registration delay in the data production workflow. To
overcome this, the European Commission’s Joint Research Centre in collaboration
with the WHO’s International Agency for Research on Cancer have computed esti-
mates of cancer incidence and mortality, for the year 2020 and for European coun-
tries, in the framework of the European Cancer Information System (ECIS).
Methods: Predicted values for the year 2020 are based on the incidence data of more
than 150 European population-based cancer registries included in ECIS, and on
mortality data provided by WHO. Ad-hoc statistical models were developed on the
basis of the most recent time trends of observed data to estimate cancer incidence
and mortality rates in each EU country for the year 2020. Estimated rates were then
applied to the projected population figures for 2020 from EUROSTAT in order to
calculate the predicted number of new cases and deaths for 2020 in 40 European
countries.
Results: The number of new cancer cases and deaths in 2020 has been estimated per
country by sex and age group, for 25 major cancer sites. The results are included and
disseminated through the European Cancer Information System (ECIS) web
application.
Conclusions: The release of up-to-date cancer incidence and mortality estimates is of
great importance to support EU evidence-based cancer policies. The homogeneity of
the estimation methods applied throughout Europe guarantees the comparability of
the estimated values between countries. Reliable and comparable estimates highlight
differences between countries in cancer incidence and mortality, thus facilitating the
identification of possible intervention areas. The applied methodology couldn’t take
into account the possible impact of the COVID-19 pandemic on the projected rates. A
future exercise to evaluate the discrepancy between projected and observed rates
will allow quantification of this impact.
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